Dashboard
Manage Tickers

NVRO NEVRO CORP

NYSE nevro.com


$ 0.00 (0 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 627.93 $ 0.00 (0 %)
DIA $ 475.32 $ 0.00 (0 %)
SPY $ 684.70 $ 0.00 (0 %)
TLT $ 92.09 $ 0.00 (0 %)
GLD $ 359.38 $ 0.00 (0 %)
$ 5.84
-- x --
-- x --
-- - --
$ 3.17 - $ 13.84
753,602
na
221.21M
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-04-2025 12-31-2024 10-K
2 11-12-2024 09-30-2024 10-Q
3 08-06-2024 06-30-2024 10-Q
4 05-07-2024 03-31-2024 10-Q
5 02-23-2024 12-31-2023 10-K
6 11-01-2023 09-30-2023 10-Q
7 08-01-2023 06-30-2023 10-Q
8 04-26-2023 03-31-2023 10-Q
9 02-21-2023 12-31-2022 10-K
10 11-02-2022 09-30-2022 10-Q
11 08-03-2022 06-30-2022 10-Q
12 05-04-2022 03-31-2022 10-Q
13 02-23-2022 12-31-2021 10-K
14 11-08-2021 09-30-2021 10-Q
15 08-04-2021 06-30-2021 10-Q
16 05-05-2021 03-31-2021 10-Q
17 02-24-2021 12-31-2020 10-K
18 11-05-2020 09-30-2020 10-Q
19 08-05-2020 06-30-2020 10-Q
20 05-05-2020 03-31-2020 10-Q
21 02-25-2020 12-31-2019 10-K
22 11-06-2019 09-30-2019 10-Q
23 08-08-2019 06-30-2019 10-Q
24 05-09-2019 03-31-2019 10-Q
25 02-21-2019 12-31-2018 10-K
26 11-05-2018 09-30-2018 10-Q
27 08-02-2018 06-30-2018 10-Q
28 05-07-2018 03-31-2018 10-Q
29 02-22-2018 12-31-2017 10-K
30 11-06-2017 09-30-2017 10-Q
31 08-07-2017 06-30-2017 10-Q
32 05-08-2017 03-31-2017 10-Q
33 02-23-2017 12-31-2016 10-K
34 11-07-2016 09-30-2016 10-Q
35 08-08-2016 06-30-2016 10-Q
36 05-09-2016 03-31-2016 10-Q
37 02-29-2016 12-31-2015 10-K
38 11-09-2015 09-30-2015 10-Q
39 08-06-2015 06-30-2015 10-Q
40 05-11-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nevro-q4-2024-gaap-eps-141-misses-079-estimate-sales-105500m-beat-102544m-estimate
Nevro Q4 2024 GAAP EPS $(1.41) Misses $(0....
03/04/2025 21:25:28

Nevro (NYSE:NVRO) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(0.79) by 78.4...

canaccord-genuity-maintains-hold-on-nevro-raises-price-target-to-585
Canaccord Genuity Maintains Hold on Nevro,...
02/07/2025 18:58:05

Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and raises the price target from $4 to $5...

demystifying-nevro-insights-from-11-analyst-reviews
Demystifying Nevro: Insights From 11 Analy...
02/07/2025 18:00:59

piper-sandler-upgrades-nevro-to-neutral-lowers-price-target-to-585
Piper Sandler Upgrades Nevro to Neutral, L...
02/07/2025 14:23:38

Piper Sandler analyst Adam Maeder upgrades Nevro (NYSE:NVRO) from Underweight to Neutral and lowers the price target from $6...

Core News & Articles
Globus Medical To Acquire Nevro For $5.85/...
02/06/2025 14:32:41

nevro-announces-q4-2024-revenue-decline-to-105m-106m-us-revenue-falls-to-91m-92m-fy24-revenue-at-408m-409m-exceeds-guidance-due-to-scs-device-replacement-surge-cash-reserves-increase-to-2925m-by-year-end
Nevro Announces Q4 2024 Revenue Decline To...
01/13/2025 14:19:33

Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024REDWOOD CI...

where-nevro-stands-with-analysts
Where Nevro Stands With Analysts
12/18/2024 20:01:09

truist-securities-maintains-hold-on-nevro-lowers-price-target-to-47
Truist Securities Maintains Hold on Nevro,...
12/18/2024 15:23:52

Truist Securities analyst Richard Newitter maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $7 to $4.7.

citigroup-maintains-neutral-on-nevro-lowers-price-target-to-5
Citigroup Maintains Neutral on Nevro, Lowe...
12/11/2024 19:16:40

Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $6 to $5.

wells-fargo-maintains-equal-weight-on-nevro-lowers-price-target-to-4
Wells Fargo Maintains Equal-Weight on Nevr...
12/11/2024 15:25:38

Wells Fargo analyst Nathan Treybeck maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $5 to $4.

canaccord-genuity-maintains-hold-on-nevro-lowers-price-target-to-4
Canaccord Genuity Maintains Hold on Nevro,...
12/09/2024 17:24:57

Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $7 to $4.

wells-fargo-reinstates-equal-weight-on-nevro-announces-5-price-target
Wells Fargo Reinstates Equal-Weight on Nev...
12/03/2024 11:32:24

Wells Fargo analyst Nathan Treybeck reinstates Nevro (NYSE:NVRO) with a Equal-Weight and announces $5 price target.

morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos
Morgan Stanley Maintains Positive MedTech ...
12/02/2024 19:29:58

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid comp...

what-analysts-are-saying-about-nevro-stock
What Analysts Are Saying About Nevro Stock
12/02/2024 16:00:14

morgan-stanley-downgrades-nevro-to-underweight-lowers-price-target-to-4
Morgan Stanley Downgrades Nevro to Underwe...
12/02/2024 14:00:17

Morgan Stanley analyst Cecilia Furlong downgrades Nevro (NYSE:NVRO) from Equal-Weight to Underweight and lowers the price ta...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/12/2024 21:08:17

why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday
Why Medical Device Firm Nevro Stock Is Tra...
11/12/2024 16:40:39

Nevro stock rises as it gains CE Mark for its HFX iQ SCS system, the first with AI-based personalized pain relief. 2024 revenue...

canaccord-genuity-maintains-hold-on-nevro-lowers-price-target-to-7
Canaccord Genuity Maintains Hold on Nevro,...
11/12/2024 16:07:03

Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $8 to $7.

peeling-back-the-layers-exploring-nevro-through-analyst-insights
Peeling Back The Layers: Exploring Nevro T...
11/12/2024 16:00:25

jmp-securities-reiterates-market-perform-on-nevro
JMP Securities Reiterates Market Perform o...
11/12/2024 15:52:07

JMP Securities analyst David Turkaly reiterates Nevro (NYSE:NVRO) with a Market Perform.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION